Argus
•
Apr 29, 2026
EXEL: Lowering target price to $49.00
Summary
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercial
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Bristol-Myers Squibb Company
May 12, 2026
•
BMY
Analyst Report: Regeneron Pharmaceuticals, Inc.
May 11, 2026
•
REGN
Market Digest: BAX, CVX, DUK, EMR, FLEX, GPN, MRK, WM, QRVO
May 08, 2026
•
CVX, GPN, WM, MRK, BAX, FLEX, EMR, DUK, QRVO
Analyst Report: Merck & Co Inc
May 08, 2026
•
MRK
Daily – Vickers Top Buyers & Sellers for 05/08/2026
May 08, 2026
•
ANGX, OPCH, ARE, SRAD, WCC, OGN, LLY, PWR, EQIX
